Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Toyota Global Sales Fall as China Demand Slumps 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Street Poller Media and The Boom of the Street Interview Ad Industry 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Add as a preferred source on Google
SAN FRANCISCO, April 05, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Solid Biosciences, Inc. (NASDAQ:SLDB) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of Massachusetts. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
